ARCHIVES

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

This article is from The Cancer Letter archive.

Vol. 36 No. 11 | November 29, 2013

Download PDF Visit The Full Archive

Related Articles

FDA Grants Orphan Designation To E7777 in T-Cell Lymphoma

August 30, 2013

Univ. of Iowa Cancer Center Wins NCI Cancer Center Grant.

July 28, 2000

Pryor Calls For Price Regulation Of Drugs In Health Reform

February 12, 1993

An Alliance of NSABP-RTOG And GOG?

March 25, 2011

In Brief: Potter Resigns As director Of Lombardi Cancer Center; Search Committee To Look for Successor

July 24, 1987

In Brief: Holleb To Retire In June As ACS Vice President; Consensus Conference On Neurofibromatosis Set

January 23, 1987